tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Caribou Biosciences (CRBU) and Intercept Pharma (ICPT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Caribou Biosciences (CRBUResearch Report) and Intercept Pharma (ICPTResearch Report).

Caribou Biosciences (CRBU)

In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on Caribou Biosciences, with a price target of $24.00. The company’s shares closed last Thursday at $7.46.

According to TipRanks.com, Cann is a 2-star analyst with an average return of 0.3% and a 41.6% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Syros Pharmaceuticals, and Intellia Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caribou Biosciences with a $26.80 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Intercept Pharma (ICPT)

JMP Securities analyst Jonathan Wolleben reiterated a Hold rating on Intercept Pharma today. The company’s shares closed last Thursday at $16.48.

According to TipRanks.com, Wolleben is a 4-star analyst with an average return of 10.5% and a 39.2% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals.

Intercept Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $22.57, implying a 49.8% upside from current levels. In a report issued on January 5, RBC Capital also maintained a Hold rating on the stock with a $15.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CRBU:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles